Karyopharm Therapeutics’ (KPTI) Neutral Rating Reaffirmed at HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $3.00 price target on the stock, down from their prior price target of $13.00. HC Wainwright’s target price suggests a potential downside of 57.20% from the stock’s previous close.

Other analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Piper Sandler reiterated an “overweight” rating and set a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research report on Monday, April 27th. Weiss Ratings lowered shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics stock opened at $7.01 on Friday. Karyopharm Therapeutics has a one year low of $3.65 and a one year high of $10.99. The firm has a market cap of $158.85 million, a PE ratio of -0.46 and a beta of 0.80. The stock’s fifty day moving average price is $9.00 and its two-hundred day moving average price is $8.23.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.21. The firm had revenue of $35.07 million for the quarter, compared to the consensus estimate of $31.40 million. Sell-side analysts expect that Karyopharm Therapeutics will post -3.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $45,000. XTX Topco Ltd bought a new stake in Karyopharm Therapeutics in the second quarter valued at $56,000. Hsbc Holdings PLC acquired a new position in shares of Karyopharm Therapeutics during the first quarter valued at about $66,000. Corient Private Wealth LLC acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $74,000. Finally, Tudor Investment Corp ET AL bought a new position in shares of Karyopharm Therapeutics during the 4th quarter worth about $95,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.